Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia: Patient considerations

Lesia V. Tchobaniouk; Erin E. McAllister; Danielle L. Bishop; Rachel M. Carpentier; Katharine R. Heins; Robert J. Haight; Jeffrey R. Bishop

doi:10.2147/PPA.S192418

Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia: Patient considerations

Lesia V. Tchobaniouk, Erin E. McAllister, Danielle L. Bishop, Rachel M. Carpentier, Katharine R. Heins, Robert J. Haight, Jeffrey R. Bishop

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral for-mulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risper-idone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.

Original language	English (US)
Pages (from-to)	2233-2241
Number of pages	9
Journal	Patient Preference and Adherence
Volume	13
DOIs	https://doi.org/10.2147/PPA.S192418
State	Published - 2019

Bibliographical note

Publisher Copyright:
© 2019 Tchobaniouk et al.

Keywords

Adherence
Antipsychotic medications
Long-acting injections
RBP-7000
Risperidone

Publisher link

10.2147/PPA.S192418

Find It

Find It at U of M Libraries

Cite this

@article{94c07c8bfa5344758c353cd2a033970c,

title = "Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia: Patient considerations",

abstract = "Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral for-mulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risper-idone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.",

keywords = "Adherence, Antipsychotic medications, Long-acting injections, RBP-7000, Risperidone",

author = "Tchobaniouk, {Lesia V.} and McAllister, {Erin E.} and Bishop, {Danielle L.} and Carpentier, {Rachel M.} and Heins, {Katharine R.} and Haight, {Robert J.} and Bishop, {Jeffrey R.}",

note = "Publisher Copyright: {\textcopyright} 2019 Tchobaniouk et al.",

year = "2019",

doi = "10.2147/PPA.S192418",

language = "English (US)",

volume = "13",

pages = "2233--2241",

journal = "Patient Preference and Adherence",

issn = "1177-889X",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia

T2 - Patient considerations

AU - Tchobaniouk, Lesia V.

AU - McAllister, Erin E.

AU - Bishop, Danielle L.

AU - Carpentier, Rachel M.

AU - Heins, Katharine R.

AU - Haight, Robert J.

AU - Bishop, Jeffrey R.

PY - 2019

Y1 - 2019

N2 - Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral for-mulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risper-idone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.

AB - Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral for-mulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risper-idone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.

KW - Adherence

KW - Antipsychotic medications

KW - Long-acting injections

KW - RBP-7000

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=85085280757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085280757&partnerID=8YFLogxK

U2 - 10.2147/PPA.S192418

DO - 10.2147/PPA.S192418

M3 - Article

C2 - 32184570

AN - SCOPUS:85085280757

SN - 1177-889X

VL - 13

SP - 2233

EP - 2241

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

ER -

Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia: Patient considerations

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this